Drug intelligence / Profile preview

CHAM

Development stage: Discontinued
Lead developer: Cornerstone Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

CHAM is a combination therapy regimen primarily investigated for relapsed/refractory Acute Myeloid Leukemia (AML). It consists of CPI-613 (devimistat), high-dose cytarabine, and mitoxantrone. CPI-613 (devimistat) is an investigational drug designed to target the altered energy metabolism and processes for the production of ATP and essential bio-intermediates characteristic of cancer cells. Cytarabine is an antimetabolite that interferes with DNA synthesis, while mitoxantrone is a topoisomerase II inhibitor. This combination aims to improve complete remission rates in older patients with AML.

Brand names: CPI-613CPI613CPI 613
Other names: CPI-613 + Cytarabine + MitoxantroneDevimistat + Cytarabine + Mitoxantrone

Targets

α-KGDH (Alpha-ketoglutarate dehydrogenase complex)PDH (Pyruvate dehydrogenase complex)

Beyond the preview

Go deeper on CHAM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHAM.

Explore the full profile